References
- Chu E, Mota AC, Fogarski MC. Antimetabolites. In: DeVita VI Jr, Hellman S, Rosenerg SA, eds. Cancer Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2001: 388–415.
- Kolesar JM, Johnson CL, Freeberg BL, et al. Warfarin-5-FU interaction - a consecutive case series. Pharmacotherapy 1999; 19: 1445-1449.
- Masci G, Magagnoli M, Zucali PA, et al. Minidose war-farin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 2003; 21: 736–739.
- Reigner B, Blesch K, Weidekamm E. Clinical pharmaco-kinetics of capecitabine. Clin Pharmacokinet 2001; 40: 85–104.
- Xeloda (capecitabine) Product monograph. Roche Pharmaceuticals. October 2004, pp 135-136.
- Copur MS, Ledakis P, Bolton M, et al. An adverse inter-action between warfarin and capecitabine: A case report and review of the literature. Clin Colorectal Cancer 2001; 1: 182–184.
- Buyck HCE, Buckley N, Leslie MD, Plowman PN. Capecitabine-induced potentiation of warfarin. Clin Oncol 2003; 15: 1 (correspondence).